Drugs / PF-05230905
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01284036 | Oct 2010 → Nov 2011 | — | Ablynx, a Sanofi company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05230905 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01284036 ↗ |
| Route | Subcutaneous | “Single dose subcutaneous” NCT01284036 ↗ |